Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:LRIG1-PPM1L

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: LRIG1-PPM1L
	FusionPDB ID: 49678
	FusionGDB2.0 ID: 49678
		Hgene	Tgene
	Gene symbol	LRIG1	PPM1L
	Gene ID	26018	151742
	Gene name	leucine rich repeats and immunoglobulin like domains 1	protein phosphatase, Mg2+/Mn2+ dependent 1L
	Synonyms	LIG-1\|LIG1	PP2C-epsilon\|PP2CE\|PPM1-LIKE
	Cytomap	3p14.1	3q25.33-q26.1
	Type of gene	protein-coding	protein-coding
	Description	leucine-rich repeats and immunoglobulin-like domains protein 1leucine-rich repeat protein LRIG1ortholog of mouse integral membrane glycoprotein LIG-1	protein phosphatase 1LPP2C epsilonProtein phosphatase 2C epsilon isoformprotein phosphatase 2C isoform epsilon
	Modification date	20200320	20200313
	UniProtAcc	Q96JA1 Main function of 5'-partner protein: FUNCTION: Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation. {ECO:0000269\|PubMed:15282549}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000273261, ENST00000383703, ENST00000496559,	ENST00000480117, ENST00000295839, ENST00000464260, ENST00000497343, ENST00000498165,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	11 X 13 X 6=858	5 X 5 X 2=50
	# samples	14	5
	** MAII score	log2(14/858*10)=-2.61555082055458 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(5/50*10)=0
Fusion gene context	PubMed: LRIG1 [Title/Abstract] AND PPM1L [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: LRIG1 [Title/Abstract] AND PPM1L [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	LRIG1(66550614)-PPM1L(160679524), # samples:2
Anticipated loss of major functional domain due to fusion event.	LRIG1-PPM1L seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. LRIG1-PPM1L seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. LRIG1-PPM1L seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. LRIG1-PPM1L seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:66550614/chr3:160679524)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across LRIG1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PPM1L (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000273261	LRIG1	chr3	66550614	-	ENST00000497343	PPM1L	chr3	160679524	+	1226	743	144	761	205
ENST00000273261	LRIG1	chr3	66550614	-	ENST00000498165	PPM1L	chr3	160679524	+	11177	743	314	1426	370
ENST00000383703	LRIG1	chr3	66550614	-	ENST00000497343	PPM1L	chr3	160679524	+	1305	822	10	840	276
ENST00000383703	LRIG1	chr3	66550614	-	ENST00000498165	PPM1L	chr3	160679524	+	11256	822	393	1505	370

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000273261	ENST00000497343	LRIG1	chr3	66550614	-	PPM1L	chr3	160679524	+	0.80724925	0.19275077
ENST00000273261	ENST00000498165	LRIG1	chr3	66550614	-	PPM1L	chr3	160679524	+	0.001000537	0.9989994
ENST00000383703	ENST00000497343	LRIG1	chr3	66550614	-	PPM1L	chr3	160679524	+	0.7994705	0.20052953
ENST00000383703	ENST00000498165	LRIG1	chr3	66550614	-	PPM1L	chr3	160679524	+	0.001002109	0.99899787

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for LRIG1-PPM1L

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
LRIG1	chr3	66550614	PPM1L	chr3	160679524	743	143	CVARGPALLDAEPTAAEYVKSRLPEA
LRIG1	chr3	66550614	PPM1L	chr3	160679524	822	143	CVARGPALLDAEPTAAEYVKSRLPEA

Top

Potential FusionNeoAntigen Information of LRIG1-PPM1L in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

LRIG1-PPM1L_66550614_160679524.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B44:03	AEPTAAEY	0.9991	0.9526	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:01	AEPTAAEY	0.9484	0.895	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:24	ALLDAEPTA	0.9926	0.5719	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:67	ALLDAEPTA	0.9926	0.5719	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:30	ALLDAEPTA	0.9926	0.5719	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:60	ALLDAEPTA	0.9925	0.5676	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:16	ALLDAEPTA	0.9922	0.5648	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:22	ALLDAEPTA	0.9917	0.6207	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:11	ALLDAEPTA	0.9915	0.6008	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:27	ALLDAEPTA	0.9899	0.6268	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:21	ALLDAEPTA	0.9895	0.6735	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:13	ALLDAEPTA	0.9852	0.7236	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:38	ALLDAEPTA	0.977	0.646	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:04	ALLDAEPTA	0.9718	0.8377	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:08	DAEPTAAEY	0.9557	0.8061	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:01	DAEPTAAEY	0.931	0.9022	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:19	LLDAEPTAA	0.9046	0.5602	7	16
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:35	ALLDAEPTA	0.9035	0.5834	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:29	ALLDAEPTA	0.8631	0.5804	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:20	ALLDAEPTA	0.8369	0.5796	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:02	DAEPTAAEY	0.7221	0.9456	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:01	DAEPTAAEY	0.7092	0.89	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:05	DAEPTAAEY	0.4538	0.6267	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:04	DAEPTAAEY	0.0435	0.9581	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:02	DAEPTAAEY	0.0435	0.9581	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:27	ALLDAEPTAA	0.9931	0.637	6	16
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:13	ALLDAEPTAA	0.9929	0.735	6	16
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:08	LDAEPTAAEY	0.9627	0.8603	8	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:38	ALLDAEPTAA	0.9479	0.6741	6	16
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A80:01	LLDAEPTAAEY	0.9943	0.5153	7	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:01	ALLDAEPTA	0.9926	0.5719	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:02	ALLDAEPTA	0.9914	0.6114	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:31	DAEPTAAEY	0.9197	0.903	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:21	DAEPTAAEY	0.7273	0.9158	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:12	DAEPTAAEY	0.0435	0.9581	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:31	LDAEPTAAEY	0.942	0.8876	8	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B44:13	AEPTAAEY	0.9991	0.9526	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B44:07	AEPTAAEY	0.9991	0.9526	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B44:26	AEPTAAEY	0.9991	0.9526	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:53	AEPTAAEY	0.9862	0.8477	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:11	AEPTAAEY	0.9641	0.8354	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:04	AEPTAAEY	0.9616	0.9059	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:06	AEPTAAEY	0.9611	0.9015	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:08	AEPTAAEY	0.9505	0.8706	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:05	AEPTAAEY	0.9484	0.895	10	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:06	ALLDAEPTA	0.9895	0.6735	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:14	ALLDAEPTA	0.9891	0.6792	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A02:03	ALLDAEPTA	0.988	0.6748	6	15
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:24	DAEPTAAEY	0.9831	0.9357	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:04	DAEPTAAEY	0.9347	0.899	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:77	DAEPTAAEY	0.931	0.9022	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:23	DAEPTAAEY	0.9283	0.9059	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:20	DAEPTAAEY	0.9216	0.9406	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:03	DAEPTAAEY	0.7778	0.8783	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:07	DAEPTAAEY	0.7702	0.8457	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:11	DAEPTAAEY	0.7533	0.9126	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:06	DAEPTAAEY	0.7425	0.9029	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:05	DAEPTAAEY	0.7092	0.89	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-A25:01	DAEPTAAEY	0.7007	0.7883	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B53:02	DAEPTAAEY	0.6765	0.5821	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B18:08	DAEPTAAEY	0.6755	0.8468	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:17	DAEPTAAEY	0.5112	0.7923	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:30	DAEPTAAEY	0.5112	0.7923	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:13	DAEPTAAEY	0.2423	0.689	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:08	DAEPTAAEY	0.2102	0.8562	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B15:11	DAEPTAAEY	0.2084	0.8721	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:43	DAEPTAAEY	0.1585	0.8601	9	18
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	HLA-B35:09	DAEPTAAEY	0.0435	0.9581	9	18

Top

Potential FusionNeoAntigen Information of LRIG1-PPM1L in HLA II

LRIG1-PPM1L_66550614_160679524.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	DRB1-0409	PALLDAEPTAAEYVK	5	20
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	DRB1-0467	PALLDAEPTAAEYVK	5	20
LRIG1-PPM1L	chr3	66550614	chr3	160679524	743	DRB1-0467	GPALLDAEPTAAEYV	4	19

Top

Fusion breakpoint peptide structures of LRIG1-PPM1L

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
383	ALLDAEPTAAEYVK	LRIG1	PPM1L	chr3	66550614	chr3	160679524	743

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of LRIG1-PPM1L

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	383	ALLDAEPTAAEYVK	-7.15543	-7.26883
HLA-B14:02	3BVN	383	ALLDAEPTAAEYVK	-4.77435	-5.80965
HLA-B52:01	3W39	383	ALLDAEPTAAEYVK	-6.80875	-6.92215
HLA-B52:01	3W39	383	ALLDAEPTAAEYVK	-4.20386	-5.23916
HLA-A11:01	4UQ2	383	ALLDAEPTAAEYVK	-7.5194	-8.5547
HLA-A11:01	4UQ2	383	ALLDAEPTAAEYVK	-6.9601	-7.0735
HLA-A24:02	5HGA	383	ALLDAEPTAAEYVK	-7.52403	-7.63743
HLA-A24:02	5HGA	383	ALLDAEPTAAEYVK	-5.82433	-6.85963
HLA-B27:05	6PYJ	383	ALLDAEPTAAEYVK	-3.28285	-4.31815
HLA-B44:05	3DX8	383	ALLDAEPTAAEYVK	-5.91172	-6.94702
HLA-B44:05	3DX8	383	ALLDAEPTAAEYVK	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of LRIG1-PPM1L

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
LRIG1-PPM1L	chr3	66550614	chr3	160679524	10	18	AEPTAAEY	GCGGAGCCTACTGCAGCTGAATAT
LRIG1-PPM1L	chr3	66550614	chr3	160679524	6	15	ALLDAEPTA	GCCCTCCTGGACGCGGAGCCTACTGCA
LRIG1-PPM1L	chr3	66550614	chr3	160679524	6	16	ALLDAEPTAA	GCCCTCCTGGACGCGGAGCCTACTGCAGCT
LRIG1-PPM1L	chr3	66550614	chr3	160679524	7	16	LLDAEPTAA	CTCCTGGACGCGGAGCCTACTGCAGCT
LRIG1-PPM1L	chr3	66550614	chr3	160679524	7	18	LLDAEPTAAEY	CTCCTGGACGCGGAGCCTACTGCAGCTGAATAT
LRIG1-PPM1L	chr3	66550614	chr3	160679524	8	18	LDAEPTAAEY	CTGGACGCGGAGCCTACTGCAGCTGAATAT
LRIG1-PPM1L	chr3	66550614	chr3	160679524	9	18	DAEPTAAEY	GACGCGGAGCCTACTGCAGCTGAATAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
LRIG1-PPM1L	chr3	66550614	chr3	160679524	4	19	GPALLDAEPTAAEYV	GGACCTGCCCTCCTGGACGCGGAGCCTACTGCAGCTGAATATGTA
LRIG1-PPM1L	chr3	66550614	chr3	160679524	5	20	PALLDAEPTAAEYVK	CCTGCCCTCCTGGACGCGGAGCCTACTGCAGCTGAATATGTAAAA

Top

Information of the samples that have these potential fusion neoantigens of LRIG1-PPM1L

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
OV	LRIG1-PPM1L	chr3	66550614	ENST00000273261	chr3	160679524	ENST00000498165	TCGA-29-1695-01A

Top

Potential target of CAR-T therapy development for LRIG1-PPM1L

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

PPM1L

chr3:66550614

chr3:160679524

ENST00000295839

26_42

234.0

Transmembrane

Helical

Tgene

PPM1L

chr3:66550614

chr3:160679524

ENST00000464260

26_42

182.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to LRIG1-PPM1L

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to LRIG1-PPM1L

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)